Newron Pharmaceuticals develops nervous system therapies as a biopharmaceutical company and commercializes Xadago, a Parkinson's disease treatment, with pharmaceutical partners.
Newron Pharmaceuticals attends investor conferences in November to present its pipeline of novel therapies for central and peripheral nervous system diseases. The biopharmaceutical company targets treatments for neurological disorders through its ongoing research programs. Participation includes key investor meetings to discuss development progress and strategic updates.
Newron Pharmaceuticals finishes patient enrollment for its Phase 3 ENIGMA-TRS 1 clinical trial, a pivotal study evaluating a potential treatment for tardive dyskinesia. The trial assesses the drug’s efficacy and safety in adults with persistent movement disorders linked to antipsychotic medications. This milestone advances the company’s pipeline in neurology, following earlier Phase 2b results.
Newron Pharmaceuticals receives an FDA clinical hold on its Phase 3 ENIGMA-TRS trial for **TRS-266**, a potential treatment for tardive dyskinesia. The company pauses patient enrollment while addressing regulatory feedback. The hold affects ongoing research but does not halt earlier-stage studies of the same compound.
Newron Pharmaceuticals updates progress on its **Phase 3 ENIGMA-TRS 2 clinical trial**, evaluating a treatment for **tardive dyskinesia**. The study assesses safety and efficacy in patients with persistent movement disorders linked to antipsychotic medications. No further details on trial outcomes or timelines are disclosed in the announcement.
Newron releases its **half-year 2026 financial results** under an ad hoc announcement. The company provides a **corporate update**, though specific metrics or strategic shifts are not detailed in the brief notice.
Newron secures a EUR 5.5 million share subscription from an investor group as part of its up to EUR 38 million financing round. The funds aim to advance the company’s Phase 3 clinical program for its evenamide drug candidate. The announcement aligns with Newron’s efforts to accelerate development of its pipeline therapies.
Newron finalizes screening for patient enrollment in its pivotal Phase 3 **ENIGMA-TRS 1** trial, evaluating **evenamide** as an add-on therapy for **treatment-resistant schizophrenia (TRS)**. The study aims to assess the drug’s efficacy in patients unresponsive to existing treatments. This milestone advances Newron’s clinical development pipeline for psychiatric disorders.
Newron Pharmaceuticals shares an update after its Type A meeting with the U.S. Food and Drug Administration (FDA). The company follows regulatory procedures under **Art. 53 LR** for investor disclosure. No specific details on outcomes or next steps are provided in the announcement.